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ABSTRACT 
Objective. The objective of the present study is to synthesize and optimize bovine serum albumin nanoparticles coated with ofloxacin drug nano 
conjugate and evaluation of control release and anti bacterial activity against clinical isolate of Pseudomonas aeruginosa,Methods.Simple 
coacervation technique was implemented for preparation of BSA nanoparticles and optimization was carried out with various parameters such as 
pH, Ethanol to BSA ratio and crosslinking time. The Nano-Drug conjugate was prepared using the optimized conditions along with ofloxacin.  The 
Nanospheres thus formed were characterized by scanning electron microscopy and the control release, drug loading efficiency and entrapment 
efficiency was studied. Anti bacterial activity was studied  with clinical isolate Pseudomonas aeruginosa adopting well diffusion assay.Results. The 
optimal pH was found to be 8.5 the ethanol to albumin ratio was fo be 5;1 and cross linking time of 8hrs which gives the higher yield of BSA 
nanoparticles.The Nanospheres thus formed were characterized using SEM which  showed a particle size of nanosphere in the range of 160-230nm. 
The drug loading efficiency and entrapment efficiency was found to be 65 and 85% respectively. The in vitro drug release profiles show 81% release 
There was a controlled and a steady release of drugs from the nanoconjugate which showed distinct activity on Pseudomonas aeruginosa  isolated 
from clinical samples.  Conclusion. Nano albumin drug conjugate as an effective anti microbial agent against pathogenic bacteria would suggest the 
possible utilization of  biocompatible non metallic nanoparticles –drug conjugate 
Keywords: Control release, nano albumin,ofloxacin, Pseudomonas aeruginosa, nanosphere, anti bacterial activity 
INTRODUCTION 
Nanotechnology refers to the research and technological 
developments at atomic, molecular, and macromolecular scales, 
which lead to the controlled manipulation and study of structures 
and devices with length scales in the range of 1–100 nm [1]. 
Biological nanoparticles are mainly developed for drug delivery 
systems as an alternative to liposome technology, in order to 
overcome the problems related to the stability of these vesicles in 
biological fluids and during storage [2].The nanoparticle technology 
used in the recent years has great significance in improving the 
efficacy of the drugs. The nanoparticles fit into colloidal drug 
delivery systems, which offer advantages of drug targeting by 
modified body distribution[3] well as the enhancement of the 
cellular uptake [4] which benefits from reduction of undesired toxic 
side effects of the free drugs[5]. With their easy accessibility in the 
body, nanoparticles can be transported via the circulation to 
different body sites, thus aiding in systemic treatments 
[6,7].Nanoparticles can be prepared from a variety of materials such 
as protein, polysaccharides and synthetic polymers. The most 
important advantage of colloidal drug carrier systems is the 
possibility of drug targeting by a modified body distribution as well 
as the improvement of the cellular uptake of a number of substances 
[8].As a result undesired toxic side effects of the free drug can be 
avoided, for example with methotrexate [9].Among of colloidal 
systems those based on proteins may be very capable. Proteins are a 
class of natural molecules that have unique functionalities and 
potential applications in both biological as well as material fields 
[10].Controlled drug release and subsequent biodegradation are 
important for developing successful formulations. Potential release 
mechanisms involve: (i) desorption of surface-bound /adsorbed 
drugs; (ii) diffusion through the carrier matrix; (iii) diffusion (in the 
case of nanocapsules) through the carrier wall; (iv) carrier matrix 
erosion; and (v) a combined erosion /diffusion process. The mode of 
delivery can be the difference between a drug’s success and failure, 
as the choice of a drug is often influenced by the way the medicine  is  
 
 
administered. Sustained (or continuous) release of a drug involves 
polymers that release the drug at a controlled rate due to diffusion 
out of the polymer or by degradation of the polymer over time. 
Pulsatile release is often the preferred method of drug delivery, as it 
closely mimics the way by which the body naturally produces 
hormones such as insulin. It is achieved by using drug-carrying 
polymers that respond to specific stimuli (e.g., exposure to light, 
changes in pH or temperature [11]. 
Nanomaterials derived from proteins, especially protein 
nanoparticles are biodegradable, non-antigenic, metabolizable and 
can also be easily amenable for surface modification and covalent 
attachment of drugs and ligands. Because of the defined primary 
structure of proteins the protein-based nanoparticles may suggest 
various possibilities for surface alteration and covalent drug 
attachment [12]. Protein nanoparticles can be utilized for the 
pulmonary delivery of protein therapeutics or can be incorporated 
into biodegradable polymer microspheres/nanospheres for 
controlled release depot or oral delivery [13,14].Nowadays active 
research is focused on the preparation of nanoparticles using 
proteins like albumin, gelatin, gliadin and legumin. Albumin, a 
protein found in blood plasma, has always been a remarkable 
molecule owing to its manifold functions and applications. Albumin 
is a biodegradable, biocompatible and less-immunogenic protein 
[15].The paramount function of albumin is in the circulatory 
system—to aid in transportation, metabolism, and distribution of 
exogenous and endogenous ligands[16].It also has an ability to act as 
an important extracellular antioxidant and to impart protection from 
free radicals and other harmful chemical agents. These unique 
attributes of albumin created a premier place for it in the drug 
therapy from time immemorial. Literature supports the use of 
modified serum albumin as a selective agent for tumor detection 
and/or therapy  or as a delivery tool of toxic compounds for 
elimination of Mycobacterium tuberculosis via receptor-mediated 
drug delivery [17].Thus, nanotechnology era also employed the well-
established properties of albumin, both human serum albumin 
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(HSA) and bovine serum albumin (BSA), for various purposes as the 
nanoparticle drug (antibodies, interferon gamma, antiviral 
compounds) targeting carriers, therapeutic enhancer of anti-cancer 
drugs, modified vehicles for drug delivery across the brain to the 
central nervous system and also across blood brain barriers[18].In 
the present study, bovine serum albumin (BSA) nnaoparticles were 
synthesized, under the optimum condition  and the optimized  
nanoparticles were coated with ofloxacin.  control release of bovine 
serum albumin (BSA) nanosphere with ofloxacin (BSA Np-OF) and 
the anti bacterial activity of  nano drug conjugate against human 
pathogenic bacteria Pseudomonas aeruginosa was discussed. 
MATERIALS AND METHODS 
Preparation of BSA nanoparticles 
Simple coacervation technique was implemented for preparation of 
BSA nanoparticles [18]. Anhydrous ethyl alcohol was added to 150 
ml BSA (5 mg/l in 10 mM Tris/HCl contained 0.02% sodium azide) 
till the solution became turbid then 150 µl of 25% glutaraldehyde 
was added for cross linking. The reaction was continued at room 
temperature (24°C). Ethanolamine was added to block the non-
reacted aldehyde functional group. Also Tween-20 was added at a 
final concentration of 0.01% (v/v) to stabilize the preparation.The 
suspension is then ultrasonicated for 30 minutes. Large aggregates 
were eliminated by centrifuge (50,000 g, 30 min, 4°C). The pellet is 
then lyophilized to form fine powder. 
 Characterization of nanoparticles 
The morphologies of the BSA nanoparticles were observed by 
scanning electron microscopy (SEM), The sample was sputtered 
with palladium gold for 30s under Polaron machine (BAL-TEC, 
Model SCDOOS, Switzerland). Afterwards, SEM was performed with 
a Carl Zeiss supra 55 (Germany) Field emission scanning electron 
microscope with the upper detector at 15 kV. The magnification was 
set at 65,000.  
Optimization of the nanoparticles preparation 
Determination of optimal pH 
The optimization of BSA nanoparticles synthesis was performed 
over a pH range between 5 and 10 based on the method of Li et al 
[21]. For the analysis, the pH value of the suspension was 
automatically adjusted by the titration unit by addition of 0.1N 
hydrochloric acid or 0.1N sodium hydroxide solution, respectively. 
At 5 predefined pH values between 6 and 10, the yield percentage of 
the nanoparticles was measured and the particle size was 
determined by SEM. 
Determination of optimal Ethanol to Albumin ratio 
The optimization of the BSA nanoparticles preparation based on the 
ethanol concentration used for coacervation process. The ethanol 
concentration used for the desolvation influences the yield and the 
particle size of the nanoparticles. Five different ethanol to albumin 
ratios were preselected using earlier works on BSA nanoparticles 
synthesis. The different ratios include 2:1,2.5:1, 3:1, 4:1 and 5:1. 
optimal ethanol concentration was determined based on the particle 
size studied using SEM and yield percentage.  
Determination of Crosslinking Time 
The crosslinking of the ethanol coacervates takes place after the 
addition of glutaraldehye. The crosslinking time influences the 
particle size and yield percentage of the nanoparticles. The cross 
linking time at a range from 6h to 16h was predetermined and the 
optimal crosslinking time for the maximum synthesis was 
determined. 
Preparation of BSA-Ofloxacin nanoconjugate 
Ofloxacin-loaded BSA nanoparticles were prepared by a desolvation 
method . Briefly, 0.2 g BSA in 1.0-mL aqueous drug 
solution(1mg/ml), titrated to desired pH and incubated at room 
temperature, was converted to nanoparticles by addition of 
desolvating agent, ethanol, at the rate of 1.0 mL/min and under 
stirring (550 rpm) at room temperature. Then another 1ml of drug 
solution was added followed by 30 minutes of stirring. 
Subsequently, 8% glutaraldehyde aqueous solution was added to 
induce particle cross-linking. The cross-linking process was 
performed under stirring of the suspension over night. Experimental 
values of drug concentration, pH, drug–BSA incubation time, and 
volumes of ethanol and glutaraldehyde were variable in 
optimization trial. 
Drug entrapment efficiency 
Ofloxacin concentration in the supernatant after the centrifugation 
of the prepared nanosphere solution was detected using the UV-Vis 
Spectrophotometer at 291nm. The drug encapsulation rate of 
Ofloxacin-NSP is calculated using the formula. 
 
Drug Loading Efficiency 
The nanosuspension with known amount of drug(10mg/20ml) was 
prepared with purified water. The suspension was then 
ultrasonicated for 30 mins for disruption and then filtered through a 
memberane. The drug content in the suspension was then detected 
by HPLC  in order to calculate the drug in the conjugate and total 
weight of the Nab-Drug conjugate. 
 
In vitro drug release study 
The drug release studies were carried out in 1xPBS. Dialysis bag was 
used to investigate invitro release of ofl-Nab.Ofl-Nab was distributed 
in water and transferred into dialysis bag and dialy ed against 
physiological saline which was ther ostated at     C and 
mechanically stirred at 75rpm. At designated intervals, a portion of 
the dialysis medium was taken for quantitation of Ofloxacin and the 
same volume of fresh medium added.The collected dialysis medium 
was syringe filtered and spectometrically read at 291nm. 
Anti bacterial activity 
The antimicrobial activity of blank albumin nanoparticles and the 
Ofloxacin coated nanoparticles were analysed on the clinically 
isolated pathogenic strains of Pseudomonas aerogenosa. The 
bacterial organisms were uniformly spread onto the sterile nutrient 
agar medium with sterile cotton swabs and blank Nab and Nab-Ofl of 
100µl withdrawn at different time interval was loaded onto the wells 
that were  ade on culture seeded agar plates and incubated for 1 -
  hrs at    C.The zone of inhibition after incubation period was 
observed and recorded. 
RESULTS AND DISCUSSION 
Preparation of BSA nanoparticles 
Nanoalbumin was prepared based on the simple coacervation 
process as described earlier. the synthesized nanoparticles was in 
the size range of 110 nm (Fig 1) but the yield percentage of this 
initial formulation was found to be less which lead to the 
optimization of the process of nanoparticles synthesis.  
Optimization of BSA nanoparticles synthesis 
The process conditions for the synthesis of the nanoparticles was 
optimized based on the factors such as pH, cross linking time, 
ethanol albumin ratio. The initial formulation parameter selection 
with blank, nanoparticles indicated that the pH and the dosage of 
ethanol significantly influenced the preparation of the nanoparticles. 
At pH less than 8 the formation of albumin nanoparticles was less 
based on the yield. With increase in pH the mean diameter of the 
nanoparticles decreased gradually and a significant increase in the 
yield percentage was also observed. Comparison of the pH values (6, 
7, 8, and 9) showed that the pH of 8 to 9 was optimal and their yield 
was equal to 90%. The yield percentage was low at pH below 7 
which were in a range of 50% to 65% which were comparatively 
lower than the yield percentages of pH above 7 which were greater 
than 80%. The ethanol concentration in the coacervation process is 
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critical as it acts as the desolvating agent. The intermittent addition 
of desolvating agent improves the reproducibility of the BSA 
nanoparticles preparation. It is noted from the optimization process 
is that the volume of ethanol added is key to the yield of controlled 
size nanoparticles. When the ratio of ethanol to 2% BSA was greater 
than 2.5:1,the yield of nanoparticles was greater or equal to 80 %. 
However with an increase in ethanol to BSA the mean diameter of 
the nanoparticles increased. 
The crosslinking of the particles by the glutaraldehyde is a critical 
factor in the synthesis of nanoparticles. The time for crosslinking 
influences the yield and particle size of the BSA nanoparticles. 
Crosslinking plays a major role in the stability and drug release of 
albumin nanoparticles. Herein the crosslinking time was varied 
between 6h and 16 hrs for to synthesize a stable,  high yielding 
process. The yield percentage of about 81% was obtained at a 
crosslinking time of 6h while the yield increased during the increase 
in the crosslinking time. The optimal cross linking time was found to 
be in the range of 8to 12 hrs based on the comparison between the 
cross linking times of 6hrs to 20 hrs(Table 1). 
Hence the optimal condition for the preparation of the blank BSA 
nanoparticles was optimized to be as pH 8, Ethanol: Albumin 4:1, 
Cross linking time of 8hrs. (Table 2) 
Table 1 shows 
Parameter Selection for Nanoalbumin 
pH 6.0 7.0 8.0 9.0 10.0 
Yield Percentage (%) 52.3±2.6 64.8±5.2 88.7±3.4 86.2±3.4 80.3±4 
 
Ethanol/BSA(V/V) 2:1 2.5:1 3:1 4:1 5:1 
Yield percentage 57.3±3.6 79.3±3.1 82.4±3.6 89.3±4.2 88.3±2.6 
 
Crosslinking time 6h 8h 12h 16h  
Yield percentage 83.7 89.2 86.5 81.2  
Table 2 shows 
 Nab Nab-Drug Conjugate 
BSA 2% 2% 
Drug  1mg/ml 
Glutaraldehyde 100% 100% 
pH 9 9 
Ethanol:BSA 4:1 4:1 
Crosslinking time 12hr 12hr 
Mean Diameter 100+nm 130+nm 
Encapsulation rate  92% 
Drug Loading  58% 
Preparation of the Nab-Ofl  nanospheres 
The preparation of the albumin Ofloxacin was prepared based on the 
conditions optimized for the preparation of blank Nab (nano 
albumin).The drug concentration of 1mg/ml was added during 
nanoparticles preparation for to be coated with BSA nanoparticles. 
The prepared Nab-ofl was found to be highly stabled in water and 
cell medium. This method leads to uniform distribution of least 
aggregated particle. The further characterization was done using 
SEM (Fig 1).  
 
Figure 1:Scanning electron micrograph of  BSA nanoparticles 
Scanning electron microscopy was used to analyze the size and 
conformational features of BSA nanoparticles and Nab-ofl conjugate. 
the micrograph showed smooth surfaces , good dispersion and 
relatively uniform size distribution in all the optimally synthesized 
nanoparticles and the mean diameter of Ofloxacin  loaded 





Figure 2: Scanning electron micrograph of nnaoalbumin-
ofloxacin conjugate 
Drug loading and entrapment efficiency 
The loading efficiency and the entrapment efficiency of the drugs on 
to the BSA is found by the spectrophotometric analysis of the drug-
BSA conjugate suspension. The unbound BSA concentration was 
found by correlating the absorbance of the supernatant after the 
centrifugation with the standard absorbance concentration ratio.  
The drug loading and entrapment efficiency of Ofloxacin was about  
64% drug encapsulation rates were 93% and 89% for Ofloxacin and 
flutamide respectively. The drug loading is found to be much higher 
than earlier studies with BSA nanoparticles. 
In vitro drug release and anti bacterial activity 
In vitro drug release of the drug was studied using 1% PBS. The 
sample was taken at regular intervals and analysed 
spectrometrically. The release percentage was calculated using the 
intial drug concentration and the release at specified time. The drug 
release was calculated for 24 hours. There was a steady release of 
drug in the early hours and a total release of about 81.8% was 
observed (Table 3 ). 
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Table 3 shows 





















In the following 6 hours, cumulative release reached 66%, in a 
sustained manner, which provides distinct activity against tested 
bacteria..Cumulative release reached almost 81% during 16  hours, 
continued till 18 hours and showed an almost released ability of the 
nanoparticle formulation. The generally sustained and controlled 
release profile of ofloxacin  facilitates the application of 
nanoparticles for the delivery of anti bacterial drugs. The 
crosslinking process with glutaraldehyde plays a major role in the 
stability and drug release from the desolvated BSANP. Anti bacterial 
activity against Pseudomonas aeruginosa  revealed there was a sharp 
increase in zone of inhibition at increased  time period and enhanced 
zone of inhibition was recorded during 18 hours with 21mm..(Figure 
1). 
  
This confirms the encapsulation of Ofloxacin by BSA nanospheres 
and also reveals the release of Ofloxacin from the nanosphere. 
Further studies are necessary for the Nab-OF system, such as 
prolonging the drug release time and enhancing the drug-loading 
rate, before the system meets clinical requirements  
CONCLUSION 
Nanotechnology has the power to radically change the way cancer is 
diagnosed, imaged and treated. Currently, there is a lot of research 
going on to design novel nanodevices capable of detecting cancer at 
its earliest stages, pinpointing it’s location within the body and 
delivering anticancer drugs specifically to malignant cells. Our aim 
was to prepare BSA nanoparticles for the effective delivery of 
ofloxacin. BSA nanoparticles preparation process was optimized by 
varying various pH from 6 to 10 wherein pH 8 was found to be most 
favourable. The desolvating agent such as Ethanol concentration was 
varied for maximum yield which proved a ratio of 4:1 ratio to be 
optimal. The crosslinking time for the process was found to be 8h. 
The process conditions were used for the encapsulation and coating 
of drugs. ofloxacin was used as the drug for the study.Further study 
will helpful to  develop the Nab-OF as the anti microbial drug. 
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